Serum gamma glutamyl transferase and alanine transaminase concentrations predict endothelial dysfunction in patients with non-alcoholic steatohepatitis

References

• Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134:1682–98.
   PubMed Web of Science ®Google Scholar
• Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med. 2005;22:1129–33.
   PubMed Web of Science ®Google Scholar
• Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–19.
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Athyros VG, Karagiannis A, Mikhailidis DP. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci. 2012;57:1109.
   PubMed Web of Science ®Google Scholar
• Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol. 2005;25:1045–50.
   PubMed Web of Science ®Google Scholar
• Assy N, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology. 2010;254:393–400.
   PubMedGoogle Scholar
• Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899–906.
   PubMed Web of Science ®Google Scholar
• Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol. 1998;82:1535–9.
   PubMed Web of Science ®Google Scholar
• Pascale A, Pais R, Ratziu V. An overview of nonalcoholic steatohepatitis: past, present and future directions. J Gastrointestin Liver Dis. 2010;19:415–23.
   PubMed Web of Science ®Google Scholar
• Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res. 2005;33:68–71.
   PubMed Web of Science ®Google Scholar
• Franzini M, Fornaciari I, Fierabracci V, Elawadi HA, Bolognesi V, Maltinti S, et al. Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liver disease. Liver Int. 2012;32:629–34.
   PubMed Web of Science ®Google Scholar
• Fletcher LM, Kwoh-Gain I, Powell EE, Powell LW, Halliday JW. Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: an aid to diagnosis. Hepatology. 1991;13:455–9.
   PubMedGoogle Scholar
• Banderas DZ, Escobedo J, Gonzalez E, Liceaga MG, Ramírez JC, Castro MG. γ-Glutamyl transferase: a marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome. Eur J Gastroenterol Hepatol. 2012;24:805–10.
   PubMed Web of Science ®Google Scholar
• Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis. 2007;191:391–6.
   PubMed Web of Science ®Google Scholar
• Westerbacka J, Cornér A, Tiikkainen M, Tamminen M, Vehkavaara S, Häkkinen AM, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia. 2004;47:1360–9.
   PubMed Web of Science ®Google Scholar
• Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91–100.
   PubMed Web of Science ®Google Scholar
• Yagmur J, Ermis N, Acikgoz N, Cansel M, Atas H, Karakus Y, et al. Elevated serum gamma-glutamyl transferase activity in patients with cardiac syndrome X and its relationship with carotid intima media thickness. Acta Cardiol. 2010;65:515–19.
   PubMed Web of Science ®Google Scholar
• Aksakal E, Tanboga IH, Kurt M, Kaygın MA, Kaya A, Isik T, et al. The relation of serum gamma-glutamyl transferase levels with coronary lesion complexity and long-term outcome in patients with stable coronary artery disease. Atherosclerosis. 2012;221:596–601.
   PubMed Web of Science ®Google Scholar
• Dogan A, Icli A, Aksoy F, Varol E, Erdogan D, Ozaydin M, et al. Gamma-glutamyltransferase in acute coronary syndrome patients without ST elevation and its association with stenotic lesion and cardiac events. Coron Artery Dis. 2012;23:39–44.
   PubMedGoogle Scholar
• Akpek M, Elcik D, Kalay N, Yarlioglues M, Dogdu O, Sahin O, et al. The prognostic value of serum gamma glutamyl transferase activity on admission in patients with STEMI undergoing primary PCI. Angiology. 2012;63:579–85.
   Google Scholar
• Schindhelm RK, Diamant M, Bakker SJ, van Dijk RA, Scheffer PG, Teerlink T, et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest. 2005;35:369–74.
   Google Scholar
• Stoner L, Erickson ML, Young JM, Fryer S, Sabatier MJ, Faulkner J, et al. There's more to flow-mediated dilation than nitric oxide. J Atheroscler Thromb. 2012;19:589–600.
   Web of Science ®Google Scholar
• Charakida M, Masi S, Lüscher TF, Kastelein JJ, Deanfield JE. Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J. 2010;31:2854–61.
   PubMed Web of Science ®Google Scholar
• Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51:595–602.
   PubMed Web of Science ®Google Scholar
• Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473–80.
   PubMed Web of Science ®Google Scholar
• Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med. 2008;121:72–8.
   PubMed Web of Science ®Google Scholar
• Turgut O, Yilmaz A, Yalta K, Karadas F, Yilmaz MB. Gamma glutamyl transferase is a promising biomarker for cardiovascular risk. Med Hypotheses. 2006;67:1060–4.
   PubMed Web of Science ®Google Scholar
• Lee DH, Gross MD, Jacobs DR. Jr; Cardiovascular Risk Development in Young Adults Study. The association of serum carotenoids and tocopherols with gamma glutamyltransferase the CARDIA study. Clin Chem. 2004;50:582–8.
   PubMed Web of Science ®Google Scholar
• Lee DH, Blomhoff R, Jacobs DR. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res. 2004;38:535–9.
   PubMed Web of Science ®Google Scholar
• Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27:127–33.
   PubMed Web of Science ®Google Scholar
• Demirkan B, Güray Y, Güray Ü, Turak O, Hajro E, Korkmaz S. The relationship between saphenous coronary bypass graft occlusion and serum gamma-glutamyltransferase activity. Turk Kardiyol Dern Ars. 2010;38:321–6.
   Google Scholar
• Nseir W, Shalata A, Marmor A, Assy N. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci. 2011;56:3439–49.
   PubMed Web of Science ®Google Scholar
• Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002;50:585–8.
   PubMed Web of Science ®Google Scholar
• Unger RH. Lipotoxic diseases. Annu Rev Med. 2002;53:319–36.
   PubMed Web of Science ®Google Scholar
• Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2005;25:193–7.
   PubMed Web of Science ®Google Scholar
• Turgut O, Tandogan I. Gamma-glutamyltransferase to determine cardiovascular risk: shifting the paradigm forward. J Atheroscler Thromb. 2011;18:177–81.
   Google Scholar
• Lee DH, Jacobs DR Jr. Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis. 2005;178:327–30.
   PubMed Web of Science ®Google Scholar
• Lee DH, Jacobs DR, Gross M, Kiefe CI, Roseman J, Lewis CE, et al. Gamma glutamyltransferase is a predictor of incident diabetes and hypertension: the CARDIA Study. Clin Chem. 2003;49:1358–66.
   PubMed Web of Science ®Google Scholar